/
Vir Biotechnology, Inc. (including its subsidiaries, referred to as Vir Bio, the Company, we, our or us ) is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Under normal conditions, our immune system is naturally equipped to protect us by identifying and eradic…
The business is unprofitable at the operating level (-699.18% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 7.6% YoY. The question is whether this is cyclical or a structural shift.
ROIC dropped from -31.31% to -35.87%, capital efficiency is deteriorating. Negative free cash flow of -$397M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$65M
▼ -7.6% YoY
Net Income (TTM)
-$443M
▲ +16.1% YoY
Op. Margin
-720.77%
▲ +92.1pp YoY
ROIC
-40.13%
▼ -4.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$450M
▲ +12.6% YoY
Op. Cash Flow (TTM)
-$446M
▲ +12.2% YoY
Net Debt
-$375M
Net Cash Position
Cash & Equiv.
$470M
5Y CAGR: -2.1%
Continue Research